Effectiveness of Statins for Oxaliplatin‐Induced Peripheral Neuropathy: A Multicenter Retrospective Observational Study

Chemotherapy-induced peripheral neuropathy, including oxaliplatin-induced peripheral neuropathy (OIPN), can have a negative impact on patient quality of life for months or even years after discontinuation of chemotherapy. Statins are commonly used for lowering cholesterol; however, evidence indicates that statins have multiple pleiotropic effects. Although statins are anticipated to exert neuroprotective actions against OIPN, no large-scale investigations have been conducted in real-world clinical settings. Our investigation aimed to determine if statins protected against OIPN. This multicentre retrospective study enrolled Japanese patients with cancer, including those with colorectal cancer (CRC), who received oxaliplatin-containing chemotherapy between April 2009 and December 2019. Propensity score matching between groups was performed to assess the relationship between the occurrence of OIPN and statin use. Among the examined 2657 patients receiving oxaliplatin, 24.7% had Grade ≥ 2 OIPN. There was no significant difference in the incidence of OIPN between the statin and non-statin groups, even after propensity score matching. However, among the matched patients with CRC (n = 510), statin use was associated with a significantly lower incidence of Grade ≥ 2 OIPN than no statin use (19.8% vs. 28.3%, respectively; p = 0.029). Our findings indicate that statins may protect against OIPN in patients with CRC.

Authors

Institutions

Publication Details

Journal
Clinical and Translational Science
Published
2025-09-29
DOI
https://doi.org/10.1111/cts.70318
Primary Topic
Cancer Treatment and Pharmacology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effectiveness of Statins for Oxaliplatin‐Induced Peripheral Neuropathy: A Multicenter Retrospective Observational Study

Keisuke Suzuki, Soichiro Ushio, Kenshi Takechi, Yoshito Zamami et al.
Clinical and Translational Science
Cancer Treatment and Pharmacology
article

Effectiveness of Statins for Oxaliplatin‐Induced Peripheral Neuropathy: A Multicenter Retrospective Observational Study

Keisuke Suzuki, Soichiro Ushio, Kenshi Takechi, Yoshito Zamami, Ayako Tsuboya, Keisuke Mine, Kenji Momo, M Hashimoto, Takehiro Kawashiri, Takahiro Niimura, Hirofumi Hamano, Yuki Hanai, Hiromi Hagiwara, Noriko Hida, Naoto Okada, Mami Uchida, Hideki Yasui, Yasutaka Sakamoto, Ryohei Fujii, Naoya Kamiyama, Keisuke Ishizawa, Masanobu Uchiyama, Masahiro Ueda, Noriaki Hidaka, Mamoru Tanaka, Kohei Uyama
article en

Abstract

Chemotherapy-induced peripheral neuropathy, including oxaliplatin-induced peripheral neuropathy (OIPN), can have a negative impact on patient quality of life for months or even years after discontinuation of chemotherapy. Statins are commonly used for lowering cholesterol; however, evidence indicates that statins have multiple pleiotropic effects. Although statins are anticipated to exert neuroprotective actions against OIPN, no large-scale investigations have been conducted in real-world clinical settings. Our investigation aimed to determine if statins protected against OIPN. This multicentre retrospective study enrolled Japanese patients with cancer, including those with colorectal cancer (CRC), who received oxaliplatin-containing chemotherapy between April 2009 and December 2019. Propensity score matching between groups was performed to assess the relationship between the occurrence of OIPN and statin use. Among the examined 2657 patients receiving oxaliplatin, 24.7% had Grade ≥ 2 OIPN. There was no significant difference in the incidence of OIPN between the statin and non-statin groups, even after propensity score matching. However, among the matched patients with CRC (n = 510), statin use was associated with a significantly lower incidence of Grade ≥ 2 OIPN than no statin use (19.8% vs. 28.3%, respectively; p = 0.029). Our findings indicate that statins may protect against OIPN in patients with CRC.

Clinical and Translational ScienceVol. 18(10)
Setsunan University (JP), SHOWA Medical University (JP), Kansai Medical University (JP), Toho University (JP), Kyushu University (JP), Asahikawa Medical University (JP), Hamamatsu University School of Medicine (JP), Fukuoka University (JP), Matsuyama University (JP), Fukuoka University Hospital (JP), Hamamatsu University Hospital (JP), Yokohama City University Hospital (JP), Okayama University Hospital (JP), Ehime University Hospital (JP), Nagoya City University Hospital (JP), Yamaguchi University Hospital (JP), Kawasaki Municipal Hospital (JP), Tokushima University Hospital (JP), National Center for Geriatrics and Gerontology (JP), SHOWA Medical University Hospital (JP), Yokohama City University (JP), Tokushima University (JP)
Openalex Percentile: Top 64%
Cancer Treatment and Pharmacology
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.